Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Lancet Oncol. 2014 Nov 12;15(13):1481–1492. doi: 10.1016/S1470-2045(14)70486-3

Table 4.

Grade 3 or 4 adverse events of interest for oxaliplatin therapy

Leucovorin and fluorouracil with
or without oxaliplatin (n=3829)
Capecitabine with or without
oxaliplatin (n=1927)
All adverse events 1731 (45%) 690 (36%)
Neutropenia 908 (24%) 91 (5%)
Diarrhoea 475 (12%) 296 (15%)
Neuropathy 295 (8%) 113 (6%)
Vomiting or nausea 203 (5%) 141 (7%)
Stomatitis, all 135 (4%) 6 (<1%)
Hand–foot syndrome 30 (<1%) 228 (12%)
Febrile neutropenia 80 (2%) 7 (<1%)
Neutropenic fever or sepsis 20 (<1%) 2 (<1%)

Data are n (%). The denominators are the numbers of patients who actually received the treatment regimens considered in this comparison.